Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Intramucosal esophageal adenocarcinoma: primum non nocere.

Li Z, Rice TW, Liu X, Goldblum JR, Williams SJ, Rybicki LA, Murthy SC, Mason DP, Raymond DP, Blackstone EH.

J Thorac Cardiovasc Surg. 2013 Jun;145(6):1519-24, 1524.e1-3. doi: 10.1016/j.jtcvs.2012.10.027. Epub 2012 Nov 14.

2.

The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens.

Leers JM, DeMeester SR, Oezcelik A, Klipfel N, Ayazi S, Abate E, Zehetner J, Lipham JC, Chan L, Hagen JA, DeMeester TR.

Ann Surg. 2011 Feb;253(2):271-8. doi: 10.1097/SLA.0b013e3181fbad42.

PMID:
21119508
3.

Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment.

Altorki NK, Lee PC, Liss Y, Meherally D, Korst RJ, Christos P, Mazumdar M, Port JL.

Ann Surg. 2008 Mar;247(3):434-9. doi: 10.1097/SLA.0b013e318163a2ff.

PMID:
18376186
4.

Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma.

Zehetner J, DeMeester SR, Hagen JA, Ayazi S, Augustin F, Lipham JC, DeMeester TR.

J Thorac Cardiovasc Surg. 2011 Jan;141(1):39-47. doi: 10.1016/j.jtcvs.2010.08.058. Epub 2010 Nov 5.

5.

Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma.

Lewis JT, Wang KK, Abraham SC.

Am J Surg Pathol. 2008 Apr;32(4):566-71. doi: 10.1097/PAS.0b013e31815bf8c7.

PMID:
18300796
6.

Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma.

Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT.

Am J Surg Pathol. 2007 Nov;31(11):1719-25.

PMID:
18059229
7.

Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma.

Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM.

Am J Surg Pathol. 2011 Jul;35(7):1045-53. doi: 10.1097/PAS.0b013e318219ccef.

PMID:
21602659
8.

Nodal metastasis and sites of recurrence after en bloc esophagectomy for adenocarcinoma.

Clark GW, Peters JH, Ireland AP, Ehsan A, Hagen JA, Kiyabu MT, Bremner CG, DeMeester TR.

Ann Thorac Surg. 1994 Sep;58(3):646-53; discussion 653-4.

PMID:
7944684
9.

Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction.

Westerterp M, Koppert LB, Buskens CJ, Tilanus HW, ten Kate FJ, Bergman JJ, Siersema PD, van Dekken H, van Lanschot JJ.

Virchows Arch. 2005 May;446(5):497-504. Epub 2005 Apr 19.

PMID:
15838647
10.

Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens.

Sepesi B, Watson TJ, Zhou D, Polomsky M, Litle VR, Jones CE, Raymond DP, Hu R, Qiu X, Peters JH.

J Am Coll Surg. 2010 Apr;210(4):418-27. doi: 10.1016/j.jamcollsurg.2010.01.003.

PMID:
20347733
11.

Clinicopathologic features of superficial esophageal cancer: results of consecutive 100 patients.

Tachibana M, Hirahara N, Kinugasa S, Yoshimura H.

Ann Surg Oncol. 2008 Jan;15(1):104-16. Epub 2007 Sep 22.

PMID:
17891442
12.

Esophagectomy for clinical high-grade dysplasia.

Rice TW, Murthy SC, Mason DP, Rybicki LA, Yerian LM, Dumot JA, Rodriguez CP, Blackstone EH.

Eur J Cardiothorac Surg. 2011 Jul;40(1):113-9. doi: 10.1016/j.ejcts.2010.10.020. Epub 2011 Jan 28.

PMID:
21277216
13.

Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies.

Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR.

Ann Surg. 2001 Oct;234(4):520-30; discussion 530-1.

14.

Limited resection for early adenocarcinoma in Barrett's esophagus.

Stein HJ, Feith M, Mueller J, Werner M, Siewert JR.

Ann Surg. 2000 Dec;232(6):733-42.

15.

Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma.

Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, Ajani JA.

Cancer. 2008 Mar 1;112(5):1020-7. doi: 10.1002/cncr.23265.

16.

Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia.

Peyre CG, DeMeester SR, Rizzetto C, Bansal N, Tang AL, Ayazi S, Leers JM, Lipham JC, Hagen JA, DeMeester TR.

Ann Surg. 2007 Oct;246(4):665-71; discussion 671-4.

PMID:
17893503
17.

Esophageal submucosa: the watershed for esophageal cancer.

Raja S, Rice TW, Goldblum JR, Rybicki LA, Murthy SC, Mason DP, Blackstone EH.

J Thorac Cardiovasc Surg. 2011 Dec;142(6):1403-11.e1. doi: 10.1016/j.jtcvs.2011.09.027.

18.

Advanced esophageal cancer in patients who underwent radiofrequency ablation for barrett esophagus with high-grade dysplasia.

Kim MP, Brown KN, Schwartz MR, Blackmon SH.

Innovations (Phila). 2013 Jan-Feb;8(1):17-22. doi: 10.1097/IMI.0b013e31828db550.

PMID:
23571789
19.

Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies.

Bergeron EJ, Lin J, Chang AC, Orringer MB, Reddy RM.

J Thorac Cardiovasc Surg. 2014 Feb;147(2):765-71: Discussion 771-3. doi: 10.1016/j.jtcvs.2013.10.003. Epub 2013 Dec 4.

20.

Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy.

Nigro JJ, Hagen JA, DeMeester TR, DeMeester SR, Theisen J, Peters JH, Kiyabu M.

Ann Surg. 1999 Sep;230(3):433-8; discussion 438-40.

Supplemental Content

Support Center